Key facts
- Orbis Medicines’s last known valuation is $34.8M (Feb 2024).
- It has raised $134.0M; the latest was Early Stage VC ($94.3M) in Jan 2025.
- Notable investors include New Enterprise Associates, Novo Holdings, Ecole Polytechnique Federale de Lausanne, Forbion, Cormorant Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Orbis Medicines
- ·The full record, as it builds
Funding rounds
No funding rounds for Orbis Medicines are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Orbis Medicines
Developer of a drug chemistry platform designed to discover orally bioavailable macrocycle drugs that can target proteins typically addressed by biologic therapies. The company's platform provides high-throughput capabilities for macrocycle design, synthesis, and testing, enabling pharmaceutical drug developers to create oral alternatives to injectable biologics for both intracellular and extracellular targets.
- Sector
- Healthcare
- HQ
- Frederiksberg, Denmark
- Founded
- 2021
- Employees
- 25
- Website
- orbismedicines.com/
- Ownership
- Privately Held (backing)
Orbis Medicines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Orbis Medicines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Orbis Medicines in its N-PORT filings yet. We sweep new filings monthly.